David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Key Points

• CEO David James Lennon sold 5,100 shares on March 2 at an average price of $3.31 for $16,881, trimming his stake by 10.27% to 44,579 shares (about $147,556); the sale was disclosed in an SEC Form 4 filing.
• WHWK traded down to $4.03 with volume of 276,413 (well above its 145,267 average), has a 50‑day/200‑day moving average of $2.93/$2.44, and a one‑year range of $1.39 to $4.48.
• Institutional ownership is about 52.08% with several funds taking new, modest stakes, and analyst coverage is mixed—two Buys, one Hold and one Sell—yielding a consensus rating of "Hold" and a $6.50 average target.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $3.31, for a total value of $16,881.00. Following the sale, the chief executive officer directly owned 44,579 shares in the company, valued at approximately $147,556.49. The trade was a 10.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Whitehawk Therapeutics Stock Performance

WHWK traded down $0.05 during trading on Tuesday, reaching $4.03. The stock had a trading volume of 276,413 shares, compared to its average volume of 145,267. The stock has a 50 day moving average of $2.93 and a two-hundred day moving average of $2.44. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $4.48.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new stake in shares of Whitehawk Therapeutics during the fourth quarter valued at approximately $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $51,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $84,000. Squarepoint Ops LLC acquired a new stake in Whitehawk Therapeutics during the 3rd quarter valued at $159,000. Finally, Marshall Wace LLP acquired a new stake in shares of Whitehawk Therapeutics in the fourth quarter worth $164,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on WHWK shares. JonesTrading began coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They set a "buy" rating and a $7.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. Finally, Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.